AU727662B2 - Peptides having antiproliferative properties - Google Patents

Peptides having antiproliferative properties Download PDF

Info

Publication number
AU727662B2
AU727662B2 AU26334/97A AU2633497A AU727662B2 AU 727662 B2 AU727662 B2 AU 727662B2 AU 26334/97 A AU26334/97 A AU 26334/97A AU 2633497 A AU2633497 A AU 2633497A AU 727662 B2 AU727662 B2 AU 727662B2
Authority
AU
Australia
Prior art keywords
peptide
accordance
nucleic acid
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU26334/97A
Other languages
English (en)
Other versions
AU2633497A (en
Inventor
Razvan T. Radulescu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19653445A external-priority patent/DE19653445C1/de
Application filed by Individual filed Critical Individual
Publication of AU2633497A publication Critical patent/AU2633497A/en
Application granted granted Critical
Publication of AU727662B2 publication Critical patent/AU727662B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU26334/97A 1996-03-26 1997-03-26 Peptides having antiproliferative properties Ceased AU727662B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19611939 1996-03-26
DE19611939 1996-03-26
DE19653445 1996-12-20
DE19653445A DE19653445C1 (de) 1996-03-26 1996-12-20 Peptide mit antineoplastischen Eigenschaften
PCT/DE1997/000643 WO1997035873A2 (de) 1996-03-26 1997-03-26 Peptide mit antiproliferativen eigenschaften

Publications (2)

Publication Number Publication Date
AU2633497A AU2633497A (en) 1997-10-17
AU727662B2 true AU727662B2 (en) 2000-12-21

Family

ID=26024147

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26334/97A Ceased AU727662B2 (en) 1996-03-26 1997-03-26 Peptides having antiproliferative properties

Country Status (10)

Country Link
US (1) US6660830B1 (https=)
EP (1) EP0892811B1 (https=)
JP (1) JP2001508643A (https=)
CN (1) CN1214694A (https=)
AT (1) ATE229977T1 (https=)
AU (1) AU727662B2 (https=)
BR (1) BR9711795A (https=)
CA (1) CA2251691A1 (https=)
NO (1) NO984415L (https=)
WO (1) WO1997035873A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2400567T3 (es) 2004-04-21 2013-04-10 The University Of Chicago Inhibidores de cinasa de la cadena ligera de miosina y su uso
US7947645B2 (en) * 2004-09-02 2011-05-24 Cognosci, Inc. APO E analogs and methods for their use
KR101364374B1 (ko) * 2005-03-14 2014-02-17 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 생활성 ｆｕｓ1 펩티드 및 나노입자-폴리펩티드 복합체
KR100729830B1 (ko) * 2005-03-24 2007-06-19 바이오스펙트럼 주식회사 페너트라틴을 이용하여 단백질의 세포투과를 증진시키는대장균용발현벡터
US9243035B2 (en) * 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US10513711B2 (en) 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
CN107406838A (zh) 2014-11-06 2017-11-28 纳幕尔杜邦公司 Rna引导的内切核酸酶向细胞中的肽介导的递送
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
AU2016338785B2 (en) 2015-10-12 2022-07-14 E. I. Du Pont De Nemours And Company Protected DNA templates for gene modification and increased homologous recombination in cells and methods of use
EP3365440B1 (en) 2015-10-20 2022-09-14 Pioneer Hi-Bred International, Inc. Restoring function to a non-functional gene product via guided cas systems and methods of use
WO2017079026A1 (en) 2015-11-06 2017-05-11 E. I. Du Pont De Nemours And Company Generation of complex trait loci in soybean and methods of use
EP3699281A1 (en) 2016-03-11 2020-08-26 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
AU2017286122A1 (en) 2016-06-14 2018-11-22 Pioneer Hi-Bred International, Inc. Use of Cpf1 endonuclease for plant genome modifications
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
CA3018430A1 (en) 2016-06-20 2017-12-28 Pioneer Hi-Bred International, Inc. Novel cas systems and methods of use
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US11519009B2 (en) 2017-01-09 2022-12-06 University Of Massachusetts Complexes for gene deletion and editing
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
CN111465689B (zh) 2017-12-15 2024-07-12 丹尼斯科美国公司 Cas9变体和使用方法
KR20200124702A (ko) 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
US12365888B2 (en) 2018-12-14 2025-07-22 Pioneer Hi-Bred International, Inc. CRISPR-Cas systems for genome editing
CA3136113A1 (en) 2019-04-05 2020-10-08 Danisco Us Inc. Methods for polynucleotide integration into the genome of bacillus using dual circular recombinant dna constructs and compositions thereof
US20220177923A1 (en) 2019-04-05 2022-06-09 Danisco Us Inc Methods for integrating a donor DNA sequence into the genome of bacillus using linear recombinant DNA constructs and compositions thereof
EP4627078A1 (en) 2022-12-01 2025-10-08 Danisco US Inc. Iterative muliplex genome engineering in microbial cells using a bidirectional selection marker system
WO2024118882A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a selection marker swapping system
WO2024118876A1 (en) 2022-12-01 2024-06-06 Genencor International Bv Iterative multiplex genome engineering in microbial cells using a recombinant self-excisable selection marker system
CN121152874A (zh) 2023-03-20 2025-12-16 先锋国际良种公司 具有改变的PAM识别的Cas多肽

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237129A1 (de) * 1992-11-03 1994-05-05 Radulescu Razvan Tudor Dr Med Anwendung der Komplementärpeptid-Theorie in der Onkologie/Kartiologie: 1. VPH = NH¶2¶-len alphaN-Me-Phe Tyr Lys alphaN-Me-Lys Val D-Tyr-COOH 2. Kalziumantagonist auf der Basis eines Komplementärpeptides zur Calmodulinbindungsstelle 3.hSNI¶B¶¶1¶¶6¶¶-¶¶2¶¶1¶[3'->5'] = NH¶2¶-Len Pro Thr His Asp Ala-COOH

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851991A (en) * 1987-08-31 1998-12-22 The Regents Of The University Of California Therapeutic use of the retinoblastoma susceptibility gene product
WO1989006703A1 (en) * 1988-01-21 1989-07-27 Massachusetts Eye And Ear Infirmary Diagnosis of retinoblastoma
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
IL106760A (en) * 1992-08-25 1999-12-31 Miles Inc Protein-nucleic acid hybrid construct for translocating an exogenous nucleic acid into a target cell and nucleus
US5625031A (en) * 1994-02-08 1997-04-29 Bristol-Myers Squibb Company Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein
EP0685493A1 (en) * 1994-06-01 1995-12-06 CANJI, Inc. Tumor suppressor fusion proteins
WO1995034647A1 (en) * 1994-06-13 1995-12-21 Vanderbilt University Compositions for and methods of enhancing delivery of nucleic acids to cells
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
DE19526174C2 (de) * 1995-07-18 1998-02-26 Friedhelm Prof Dr Herrmann Mittel gegen Tumorwachstum

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237129A1 (de) * 1992-11-03 1994-05-05 Radulescu Razvan Tudor Dr Med Anwendung der Komplementärpeptid-Theorie in der Onkologie/Kartiologie: 1. VPH = NH¶2¶-len alphaN-Me-Phe Tyr Lys alphaN-Me-Lys Val D-Tyr-COOH 2. Kalziumantagonist auf der Basis eines Komplementärpeptides zur Calmodulinbindungsstelle 3.hSNI¶B¶¶1¶¶6¶¶-¶¶2¶¶1¶[3'->5'] = NH¶2¶-Len Pro Thr His Asp Ala-COOH

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RADULESCU, R.T. BIOCHEM BIOPHYS. RES. COMM. 246,1, PP97-102 (1995) *

Also Published As

Publication number Publication date
WO1997035873A3 (de) 1997-12-31
JP2001508643A (ja) 2001-07-03
EP0892811A2 (de) 1999-01-27
CN1214694A (zh) 1999-04-21
US6660830B1 (en) 2003-12-09
ATE229977T1 (de) 2003-01-15
EP0892811B1 (de) 2002-12-18
WO1997035873A2 (de) 1997-10-02
AU2633497A (en) 1997-10-17
BR9711795A (pt) 2000-06-06
NO984415D0 (no) 1998-09-22
NO984415L (no) 1998-09-22
CA2251691A1 (en) 1997-10-02

Similar Documents

Publication Publication Date Title
AU727662B2 (en) Peptides having antiproliferative properties
Hinds et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes
CA2667537C (en) Metastin derivatives and use thereof
EP2113513A2 (en) Metastin derivatives and use thereof
CA2634647C (en) Metastin derivatives and use thereof
EP2277900A1 (en) Metastin derivative and use thereof
JP2008521759A (ja) ＢＨ３−ｏｎｌｙタンパク質のＢＨ３ドメイン配列を含む融合タンパク質
WO1998007858A9 (en) HUMAN POLYHOMEOTIC 1(hphl) ACTS AS A TUMOR SUPPRESSOR
US20090099334A1 (en) Metastin derivatives and use thereof
JPWO2008081812A1 (ja) 抗腫瘍ペプチド及びその利用
EP3604345B1 (en) Antitumor peptide having pd-1 signal sequence and utilization thereof
Kong et al. Design, synthesis and antitumor activity of Ascaphin-8 derived stapled peptides based on halogen–sulfhydryl click chemical reactions
JP7329173B2 (ja) 抗腫瘍ペプチドおよびその利用
JP7194928B2 (ja) 抗腫瘍ペプチドおよびその利用
US7615534B2 (en) Antimicrobial peptides and use thereof
JP7345753B2 (ja) 抗腫瘍ペプチドおよびその利用
Yamada et al. Structure, expression and function of mouse laminin
JP2002510708A (ja) 転写因子とその使用
CN118021995A (zh) 多肽在制备用于预防和/或治疗骨肉瘤的药物中的应用
EP0902088A2 (de) Petide mit antiproliferativen Eigenschaften
JP2003277290A (ja) 細胞周期制御組成物およびその使用方法
CN1972959A (zh) 转移素衍生物及其用途
HK1135711A (en) Metastin derivatives and use thereof
KR20070031949A (ko) 메타스틴 유도체 및 이의 용도
WO2007040212A1 (ja) 神経分化抑制ペプチド及びその利用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)